Abnova Taiwan Corp (4133) - Total Assets
Based on the latest financial reports, Abnova Taiwan Corp (4133) holds total assets worth NT$1.32 Billion TWD (≈ $41.49 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4133 net assets for net asset value and shareholders' equity analysis.
Abnova Taiwan Corp - Total Assets Trend (2008–2024)
This chart illustrates how Abnova Taiwan Corp's total assets have evolved over time, based on quarterly financial data.
Abnova Taiwan Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Abnova Taiwan Corp's total assets of NT$1.32 Billion consist of 69.0% current assets and 31.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 32.0% |
| Accounts Receivable | NT$49.87 Million | 3.6% |
| Inventory | NT$451.89 Million | 32.3% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$62.69 Million | 4.5% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Abnova Taiwan Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 4133 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abnova Taiwan Corp's current assets represent 69.0% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 32.0% of total assets in 2024, up from 23.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 8.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 32.3% of total assets.
Abnova Taiwan Corp Competitors by Total Assets
Key competitors of Abnova Taiwan Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Abnova Taiwan Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.77 | 13.40 | 10.38 |
| Quick Ratio | 7.62 | 7.21 | 4.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$839.93 Million | NT$881.26 Million | NT$699.27 Million |
Abnova Taiwan Corp - Advanced Valuation Insights
This section examines the relationship between Abnova Taiwan Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 3.3% |
| Total Assets | NT$1.40 Billion |
| Market Capitalization | $41.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Abnova Taiwan Corp's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Abnova Taiwan Corp's assets grew by 3.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Abnova Taiwan Corp (2008–2024)
The table below shows the annual total assets of Abnova Taiwan Corp from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.40 Billion ≈ $44.14 Million |
+3.34% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.71 Million |
-1.39% |
| 2022-12-31 | NT$1.37 Billion ≈ $43.31 Million |
+7.15% |
| 2021-12-31 | NT$1.28 Billion ≈ $40.42 Million |
-0.89% |
| 2020-12-31 | NT$1.29 Billion ≈ $40.79 Million |
+2.42% |
| 2019-12-31 | NT$1.26 Billion ≈ $39.82 Million |
-2.39% |
| 2018-12-31 | NT$1.29 Billion ≈ $40.80 Million |
-0.67% |
| 2017-12-31 | NT$1.30 Billion ≈ $41.08 Million |
+4.45% |
| 2016-12-31 | NT$1.25 Billion ≈ $39.33 Million |
-0.06% |
| 2015-12-31 | NT$1.25 Billion ≈ $39.35 Million |
-4.50% |
| 2014-12-31 | NT$1.31 Billion ≈ $41.21 Million |
+1.77% |
| 2013-12-31 | NT$1.29 Billion ≈ $40.49 Million |
-0.53% |
| 2012-12-31 | NT$1.29 Billion ≈ $40.71 Million |
-4.66% |
| 2011-12-31 | NT$1.36 Billion ≈ $42.70 Million |
+1.58% |
| 2010-12-31 | NT$1.33 Billion ≈ $42.03 Million |
+2.19% |
| 2009-12-31 | NT$1.31 Billion ≈ $41.13 Million |
+52.33% |
| 2008-12-31 | NT$857.02 Million ≈ $27.00 Million |
-- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag… Read more